Prof. Dr. Dr. Gabriele G. Schiattarella MD PhD

I am a cardiologist-scientist who integrates experimental, computational, and clinical research to advance the prevention and treatment of cardiometabolic diseases, particularly heart failure with preserved ejection fraction (HFpEF). My work focuses on the complex interplay between cardiac metabolism, interorgan crosstalk, and cardiovascular health, with a strong emphasis on lifestyle interventions, exercise, and precision prevention strategies. Currently, I lead a research group at the Deutsches Herzzentrum der Charité at Charité University Medical Center and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin.

My team investigates how metabolic alterations contribute to HFpEF and broader cardiometabolic syndromes, such as metabolic dysfunction-associated steatotic liver disease (MASLD). A key aspect of our research is understanding how systemic metabolic stressors drive cardiovascular disease progression beyond traditional risk factors like obesity. By leveraging advanced omics technologies, mechanistic studies in preclinical models, and clinical research, we aim to identify novel biomarkers and therapeutic targets for precision prevention. This includes elucidating the genetic and molecular mechanisms linking metabolic dysfunction to HFpEF and developing targeted interventions to mitigate cardiovascular risk.

Our translational approach spans from fundamental discovery to real-world applications, integrating systems biology with clinical research to inform personalized prevention strategies. By bridging cardiovascular and metabolic research, we strive to redefine how cardiometabolic diseases are detected, treated, and ultimately prevented. My research is supported by competitive funding from organizations such as the European Research Council (ERC), Deutsche Forschungsgemeinschaft (DFG), and the German Center for Cardiovascular Research (DZHK).

Through interdisciplinary collaboration, I am committed to advancing innovative strategies that improve cardiometabolic health, prevent HFpEF progression, and optimize patient outcomes.